VRAX
NASDAQVirax Biolabs Group Limited
Price$0.20-0.00 (-0.05%)
02:00 PM07:30 PM
News · 26 weeks21+200%
2025-12-142026-06-07
Mix1590d
- Insider6(40%)
- SEC Filings5(33%)
- Other4(27%)
Latest news
25 items- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesLONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early performance metrics that Virax believes support continued development and advancement into larger clinical validation.
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Virax Biolabs Group LimitedSCHEDULE 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersVirax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress.LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation. Together, these materials outline Virax's current strategic and commercial framework and the m
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Haight Nelson M3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- PRVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationLONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (
- INSIDERSEC Form 3 filed by new insider Mccracken Nigel William3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Foster James Alexander Cunliffe3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Norton Evan Michael3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Davis Jason3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- INSIDERSEC Form 3 filed by new insider Miller Iain David3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Virax Biolabs Group LimitedSCHEDULE 13G - Virax Biolabs Group Ltd (0001885827) (Subject)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 424B3 filed by Virax Biolabs Group Limited424B3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form EFFECT filed by Virax Biolabs Group LimitedEFFECT - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form F-3 filed by Virax Biolabs Group LimitedF-3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form D filed by Virax Biolabs Group LimitedD - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces Closing of $5 Million Private PlacementExtends cash runway into first half of 2028, beyond planned completion of ViraxImmune™ US based regulatory study in post-acute sequelae of COVID-19 ("PASC", or long COVID) and submission to the FDA, completion of UK based regulatory study in post-acute infection syndrome (PAIS) and submission to MHRA along with expansion of our immune-profiling platform and partnerships.LONDON, Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today the closing of its previously announced private placement of its securities for total gross proceed
- PRVirax Biolabs Group Limited Announces $5 Million Private PlacementLONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option in a private placement . The prefer
- PRVirax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to ShareholdersVirax Biolabs' proprietary in-development diagnostic technology for post-acute infection syndromes ("PAIS"), such as Long COVID, positions the Company for an important data year ahead, following a series of recent clinical and operational milestones over the past 12 months. LONDON, Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, today highlighted key milestones, achievements and clinical progress while outlining its strategic priorities for 2026 in a letter to shareholders and investors.
VRAX FAQ
7 questionsWhat does Virax Biolabs Group Limited do?
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that...Where does VRAX stock trade?
Virax Biolabs Group Limited (VRAX) is listed on NASDAQ.What sector and industry is VRAX in?
Virax Biolabs Group Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Virax Biolabs Group Limited go public?
Virax Biolabs Group Limited (VRAX) completed its IPO in 2022.What are analysts saying about VRAX?
Virax Biolabs Group Limited has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2025-03-31. Recent price targets cluster around $300.00.What companies are similar to VRAX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), ORKA (Oruka Therapeutics Inc.), NNNN (Anbio Biotechnology). Compare VRAX side-by-side with any of them on Quantisnow.How can I track VRAX on Quantisnow?
Quantisnow aggregates Virax Biolabs Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRAX to receive live email and push alerts on every new disclosure.